The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Open accessAbstract
The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of cardiotoxicity. It has been calculated that approximately 10% of patients treated with doxorubicin or its derivatives will develop cardiac complications up to 10 years after the cessation of chemotherapy. Oxidative stress has been established as the primary cause of cardiotoxicity. However, interventions reducing oxidative stress have not been successful at reducing the incidence of cardiotoxicity in patients treated with doxorubicin. New insights into the cardiomyocyte response to oxidative stress demonstrate that underlying differences between in vitro and in vivo toxicities may modulate the response to superoxide radicals and related compounds. This has led to potentially new uses for pre-existing drugs and new avenues of exploration to find better pharmacotherapies and interventions for the prevention of cardiotoxicity. However, much work still must be done to validate the clinical utility of these new approaches and proposed mechanisms. In this review, the authors have reviewed the molecular mechanisms of the pathogenesis of acute and chronic doxorubicin-induced cardiotoxicity and propose potential pharmacological interventions and treatment options to prevent or reverse this specific type of heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Suliman, H. B., Carraway, M. S., Ali, A. S., Reynolds, C. M., Welty-Wolf, K. E., & Piantadosi, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32967 · Cited by 257
RetractedMinotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β
Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., & Yuan, J. (2000) · Nature · doi:10.1038/47513 · Cited by 3,256
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Role of oxidative stress in cardiovascular diseases
Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018060-00002 · Cited by 1,467
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
The biosynthesis and functional role of cardiolipin
Schlame, M., Rua, D., & Greenberg, M. L. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00005-9 · Cited by 810
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Lüscher, T. F., & Barton, M. (2000) · Circulation · doi:10.1161/01.cir.102.19.2434 · Cited by 596
Piantadosi, C. A., Carraway, M. S., Babiker, A., & Suliman, H. B. (2008) · Circulation Research · doi:10.1161/01.res.0000338597.71702.ad · Cited by 578
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Energy metabolism in heart failure
Ventura‐Clapier, R., Garnier, A., & Veksler, V. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055095 · Cited by 499
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Self-citationHershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., & Jacobson, J. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1242 · Cited by 390
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 376
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366
Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005) · Circulation · doi:10.1161/01.cir.0000160359.49478.c2 · Cited by 355
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308033200 · Cited by 304
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
WANG, S., KOTAMRAJU, S., KONOREV, E., KALIVENDI, S., JOSEPH, J., & KALYANARAMAN, B. (2002) · Biochemical Journal · doi:10.1042/bj20020752 · Cited by 286
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Hydrogen Peroxide Stimulates the Ca2+ Release Channel from Skeletal Muscle Sarcoplasmic Reticulum
Favero, T. G., Zable, A. C., & Abramson, J. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25557 · Cited by 258
Kremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Shan, Y. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00229-3 · Cited by 235
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235
Molecular Basis of Anthracycline-Induced Cardiotoxicity and Its Prevention
Horenstein, M. S., Vander Heide, R. S., & L'Ecuyer, T. J. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3043 · Cited by 228
Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice
Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004) · Circulation · doi:10.1161/01.cir.0000146889.46519.27 · Cited by 226
Kalivendi, S. V., Kotamraju, S., Zhao, H., Joseph, J., & Kalyanaraman, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106829200 · Cited by 225
Georgakopoulos, P., Roussou, P., Matsakas, E., Karavidas, A., Anagnostopoulos, N., Marinakis, T., Galanopoulos, A., Georgiakodis, F., Zimeras, S., Kyriakidis, M., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21840 · Cited by 222
Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, Y., Takanabe-Mori, R., Nishi, E., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq148 · Cited by 208
Mukhopadhyay, P., Bátkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Haskó, G., Zsengeller, Z., Gerard, N. P., Liaudet, L., Kunos, G., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.057 · Cited by 207
Kalivendi, S. V., Konorev, E. A., Cunningham, S., Vanamala, S. K., Kaji, E. H., Joseph, J., & Kalyanaraman, B. (2005) · Biochemical Journal · doi:10.1042/bj20050285 · Cited by 205
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Patel, V., Kashiwaya, Y., Liaudet, L., Evgenov, O. V., Mackie, K., Haskó, G., & Pacher, P. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvp369 · Cited by 200
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti, F. M., Bristow, M. R., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., Brown, B. W., Hannigan, J. F., Meyers, F. J., & Mitchell, E. P. (1986) · PubMed · Cited by 197
Ueno, M., Kakinuma, Y., Yuhki, K.-I., Murakoshi, N., Iemitsu, M., Miyauchi, T., & Yamaguchi, I. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0050980 · Cited by 189
Arai, M., Yoguchi, A., Takizawa, T., Yokoyama, T., Kanda, T., Kurabayashi, M., & Nagai, R. (2000) · Circulation Research · doi:10.1161/01.res.86.1.8 · Cited by 189
Effects by doxorubicin on the myocardium are mediated by oxygen free radicals
Xu, M. F., Tang, P. L., Qian, Z. M., & Ashraf, M. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)00990-5 · Cited by 185
Elevated B-type natriuretic peptide levels after anthracycline administration
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., Kurabayashi, M., Yamaoki, K., Mitani, K., Hirai, H., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89908 · Cited by 185
SPALLAROSSA, P., ALTIERI, P., GARIBALDI, S., GHIGLIOTTI, G., BARISIONE, C., MANCA, V, FABBI, P., BALLESTRERO, A., BRUNELLI, C., & BARSOTTI, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.009 · Cited by 182
Andrieu‐Abadie, N., Jaffrézou, J., Hatem, S., Laurent, G., Levade, T., & Mercadier, J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1501 · Cited by 182
Fan, G.-C., Zhou, X., Wang, X., Song, G., Qian, J., Nicolaou, P., Chen, G., Ren, X., & Kranias, E. G. (2008) · Circulation Research · doi:10.1161/circresaha.108.182832 · Cited by 178
Extracellular Heat Shock Protein 60, Cardiac Myocytes, and Apoptosis
Kim, S.-C., Stice, J. P., Chen, L., Jung, J. S., Gupta, S., Wang, Y., Baumgarten, G., Trial, J., & Knowlton, A. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209643 · Cited by 178
Yang, L. L., Gros, R., Kabir, M. G., Sadi, A., Gotlieb, A. I., Husain, M., & Stewart, D. J. (2004) · Circulation · doi:10.1161/01.cir.0000105701.98663.d4 · Cited by 177
Pieske, B., Beyermann, B., Breu, V., Löffler, B. M., Schlotthauer, K., Maier, L. S., Schmidt-Schweda, S., Just, H., & Hasenfuss, G. (1999) · Circulation · doi:10.1161/01.cir.99.14.1802 · Cited by 173
Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.541 · Cited by 173
Pein, F., Sakiroglu, O., Dahan, M., Lebidois, J., Merlet, P., Shamsaldin, A., Villain, E., de Vathaire, F., Sidi, D., & Hartmann, O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601904 · Cited by 171
Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in Mice
Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., Kroemer, H. K., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.004 · Cited by 169
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., & Santos, M. M. (2003) · Blood · doi:10.1182/blood-2003-03-0869 · Cited by 168
Neilan, T. G., Blake, S. L., Ichinose, F., Raher, M. J., Buys, E. S., Jassal, D. S., Furutani, E., Perez-Sanz, T. M., Graveline, A., Janssens, S. P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.652339 · Cited by 167
Self-citationGoormaghtigh, E., Chatelain, P., Caspers, J., & Ruysschaert, J. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90050-7 · Cited by 166
Tatlıdede, E., Şehırlı, Ö., Velioğlu‐Öğünç, A., Çetınel, Ş., Yeğen, B. Ç., Yarat, A., Süleymanoğlu, S., & Şener, G. (2009) · Free Radical Research · doi:10.1080/10715760802673008 · Cited by 164
Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J., & Fitzgerald, D. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11334 · Cited by 159
Das, A., Durrant, D., Mitchell, C., Mayton, E., Hoke, N. N., Salloum, F. N., Park, M. A., Qureshi, I., Lee, R., Dent, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006965107 · Cited by 159
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J., & Fitzgerald, D. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111334 · Cited by 159
Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation
Maejima, Y., Adachi, S., Morikawa, K., Ito, H., & Isobe, M. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.10.012 · Cited by 156
Increased risk of cardiac dysfunction after anthracyclines in girls
Silber, J. H., Jakacki, R. I., Larsen, R. L., Goldwein, J. W., & Barber, G. (1993) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950210704 · Cited by 151
Cardiotoxicity of doxorubicin and other anthracycline derivatives
Jain, D. (2000) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2000.103324 · Cited by 149
Pani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., & Galeotti, T. (2000) · PubMed · Cited by 145
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
McKillop, J. H., Bristow, M. R., Goris, M. L., Billingham, M. E., & Bockemuehl, K. (1983) · American Heart Journal · doi:10.1016/0002-8703(83)90651-8 · Cited by 144
NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis
Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Nevière, R., & Lancel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.085 · Cited by 142
Lebrecht, D., Geist, A., Ketelsen, U., Haberstroh, J., Setzer, B., & Walker, U. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707294 · Cited by 136
Klewer, S. E., Goldberg, S. J., Donnerstein, R. L., Berg, R. A., & Hutter, J. J. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90497-b · Cited by 133
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M., Bjork, J. A., & Wallace, K. B. (2010) · Toxicology · doi:10.1016/j.tox.2010.01.019 · Cited by 131
Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., & Sakurai, M. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1155 · Cited by 130
Rayner, K. J., Chen, Y.-X., McNulty, M. S., Simard, T., Zhao, X., Wells, D. J., de Belleroche, J., & O’Brien, E. R. (2008) · Circulation Research · doi:10.1161/circresaha.108.172155 · Cited by 128
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126
Nitobe, J. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00646-6 · Cited by 126
Ibrahim, M. A., Ashour, O. M., Ibrahim, Y. F., EL-Bitar, H. I., Gomaa, W. M., & Abdel-Rahim, S. R. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.05.007 · Cited by 126
Jang, Y. M., Kendaiah, S., Drew, B., Phillips, T., Selman, C., Julian, D. A., & Leeuwenburgh, C. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.053 · Cited by 126
Caroni, P., Villani, F., & Carafoli, E. (1981) · FEBS Letters · doi:10.1016/0014-5793(81)81115-5 · Cited by 123
Early Detection of Doxorubicin Cardiomyopathy Using Two-Dimensional Strain Echocardiography
Migrino, R. Q., Aggarwal, D., Konorev, E. A., Brahmbhatt, T., Bright, M., & Kalyanaraman, B. (2007) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2007.07.018 · Cited by 118
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118
Mihm, M. J., Yu, F., Weinstein, D. M., Reiser, P. J., & Bauer, J. A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704495 · Cited by 115
Tjeerdsma, G., Meinardi, M. T., van der Graaf, W. T. A., van den Berg, M. P., Mulder, N. H., Crijns, H. J. G. M., de Vries, E. G. E., & van Veldhuisen, D. J. (1999) · Heart · doi:10.1136/hrt.81.4.419 · Cited by 115
Self-citationSacco, G., Bigioni, M., Evangelista, S., Goso, C., Manzini, S., & Maggi, C. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00782-8 · Cited by 113
Solem, L. E., Heller, L. J., & Wallace, K. B. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0095 · Cited by 111
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1344 · Cited by 111
Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH
Deng, S., Kruger, A., Kleschyov, A. L., Kalinowski, L., Daiber, A., & Wojnowski, L. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.11.013 · Cited by 110
The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity
Cole, M. P., Chaiswing, L., Oberley, T. D., Edelmann, S. E., Piascik, M. T., LIN, S., Kiningham, K. K., & Clair, D. K. S. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.07.012 · Cited by 110
Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure
Tallaj, J. A., Franco, V., Rayburn, B. K., Pinderski, L. J., Benza, R. L., Pamboukian, S. V., Foley, B. A., & Bourge, R. C. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.12.108 · Cited by 100
Xiong, Y., Liu, X., Lee, C.-P., Chua, B. H. L., & Ho, Y.-S. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.02.024 · Cited by 96
Doxorubicin (adriamycin) cardiomyopathy.
Saltiel, E., & McGuire, W. P. (1983) · PubMed Central · Cited by 95
Cardiac function in Wilms' tumor survivors.
Sørensen, K. E., Levitt, G., Sebag‐Montefiore, D., Bull, C., & Sullivan, I. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1546 · Cited by 95
Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy
Sayed‐Ahmed, M. M., Khattab, M. M., Gad, M. Z., & Osman, A. M. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-148.x · Cited by 91
Moens, A. L., Leyton-Mange, J. S., Niu, X., Yang, R., Cingolani, O. H., Arkenbout, E. K., Champion, H. C., Bedja, D., Gabrielson, K. L., Chen, J., et al. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.06.005 · Cited by 91
Self-citationKeung, E. C., Toll, L., Ellis, M., & Jensen, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115241 · Cited by 86
Duquaine, D. C., Hirsch, G. A., Chakrabarti, A. K., Han, Z., Kehrer, C., Brook, R. D., Joseph, J., Schott, A. F., Kalyanaraman, B., Vasquez-Vivar, J., et al. (2003) · Vascular Medicine · doi:10.1191/1358863x03vm476oa · Cited by 85
Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury
Gabrielson, K. L., Bedja, D., Pin, S., Tsao, A. L., Gama, L., Yuan, B., & Muratore, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3721 · Cited by 81
Self-citationReversibility of Severe Left Ventricular Dysfunction Due to Doxorubicin Cardiotoxicity
Saini, J., RICH, M. W., & LYSS, A. P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-814 · Cited by 79
Papadopoulou, L. C., Theophilidis, G., Thomopoulos, G. N., & Tsiftsoglou, A. S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00305-0 · Cited by 75
Solution chemistry studies of adriamycin-iron complexes present in vivo
May, P. M., Williams, G. K., & Williams, D. R. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90189-9 · Cited by 69
Captopril ameliorates myocardial and hematological toxicities induced by adriamycin
Al‐Shabanah, O. A., Mansour, M. A., El‐Kashef, H. A., & Al‐Bekairi, A. M. (1998) · IUBMB Life · doi:10.1080/15216549800202802 · Cited by 69
Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice
Vedam, K., Nishijima, Y., Druhan, L. J., Khan, M., Moldovan, N. I., Zweier, J. L., & Ilangovan, G. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01047.2009 · Cited by 69
Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes
Peng, X., Guo, X., Borkan, S. C., Bharti, A. K., Kuramochi, Y., Calderwood, S. K., & Sawyer, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410838200 · Cited by 68
Di, X. M., Gennings, C., Bear, H. D., Graham, L., Sheth, C. M., White, K. L., & Gewirtz, D. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0765-7 · Cited by 63
Lanzarini, L. F., Bossi, G., Laudisa, M. L., Klersy, C., & Aricò, M. (2000) · American Heart Journal · doi:10.1067/mhj.2000.108237 · Cited by 60
Engert, A., Josting, A., Haverkamp, H., Villalobos, M., Lohri, A., Sökler, M., Zijlstra, J. M., Sturm, I., Topp, M. S., Rank, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1835 · Cited by 59
van Acker, S. A. B. E., Boven, E., Kuiper, K. K. J., van den Berg, D., Grimbergen, J. A., Kramer, K., Bast, A., & van der Vijgh, W. J. F. (1997) · PubMed · Cited by 58
de Tassigny, A. D., Berdeaux, A., Souktani, R., Henry, P., & Ghaleh, B. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.11.002 · Cited by 53
Doxorubicin cardiotoxicity in children
Biancaniello, T. M., Meyer, R. A., Wong, K. Y., Sager, C., & Kaplan, S. (1980) · The Journal of Pediatrics · doi:10.1016/s0022-3476(80)80128-4 · Cited by 49
Tokarska-Schlattner, M., Lucchinetti, E., Zaugg, M., Kay, L., Gratia, S., Guzun, R., Saks, V. A., & Schlattner, U. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00360.2009 · Cited by 49
Goetzenich, A., Hatam, N., Zernecke, A., Weber, C., Czarnotta, T., Autschbach, R., & Christiansen, S. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.06.025 · Cited by 48
Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment
Youn, H., Kim, H., Jeon, M.-H., Lee, J.-H., Seo, Y.-J., Lee, J. H., & Lee, J. H. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-2541-2 · Cited by 47
de Tassigny, A. D., Souktani, R., Henry, P., Ghaleh, B., & Berdeaux, A. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00273.x · Cited by 46
Bjelogrlić, S., Radić, J., Jović, V., & Radulovic, S. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_166.x · Cited by 46
Transfusion Iron Overload in Adults with Acute Leukemia: Manifestations and Therapy
Barton, J. C., & Bertoli, L. F. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40691-3 · Cited by 46
Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues
Kashfi, K., Israel, M., Sweatman, T. W., Seshadri, R., & Cook, G. A. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90438-q · Cited by 45
Chacon, E., Ulrich, R. G., & Acosta, D. (1992) · Biochemical Journal · doi:10.1042/bj2810871 · Cited by 45
Coordinated Upregulation of the Cardiac Endothelin System in a Rat Model of Heart Failure
Picard, P., Smith, P., Monge, J. C., Rouleau, J. L., Nguyen, Q. T., Calderone, A., & Stewart, D. J. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199800001-00082 · Cited by 44
Pediatric heart transplantation for anthracycline cardiomyopathy: Cancer recurrence is rare
Ward, K. M., Binns, H. J., Chin, C. C., Webber, S. A., Canter, C. E., & Pahl, E. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2003.08.014 · Cited by 42
Nicolay, K., Aue, W. P., Seelig, J., van Echteld, C. J. A., Ruigrok, T. J. C., & KRUIJFF, B. D. (1987) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(87)90234-5 · Cited by 40
Nitric Oxide Synthase Expressions in ADR-induced Cardiomyopathy in Rats
Liu, B., Li, H., Qu, H., & Sun, B. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.6.759 · Cited by 40
Anandamide Preserves Cardiac Function and Geometry in an Acute Doxorubicin Cardiotoxicity Rat Model
Hydock, D. S., Lien, C., & Hayward, R. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248408329449 · Cited by 36
Schroeder, P. E., & Hasinoff, B. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005546 · Cited by 33
Tripathy, D., Seidman, A. D., Keefe, D. L., Hudis, C. A., Paton, V. E., & Liebérman, G. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.033 · Cited by 33
Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity
Kim, D., Kim, H., Woo, E., Kwon, D., Kim, M., Chae, S., & Chae, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.045 · Cited by 32
Thomas, C., Carr, A. C., & Winterbourn, C. C. (1994) · Free Radical Research · doi:10.3109/10715769409056591 · Cited by 30
Anthracycline‐induced cardiotoxicity in children with malignancies
GODOY, L. Y., Fukushige, J., Igarashi, H., Matsuzaki, A., & Ueda, K. (1997) · Pediatrics International · doi:10.1111/j.1442-200x.1997.tb03579.x · Cited by 28
[Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line].
Liu, B., Bai, Q.-X., Chen, X., Gao, G., & Gu, H. (2007) · PubMed · Cited by 24
van Acker, S. A. B. E., Voest, E. E., Beems, D. B., Madhuizen, H. T., de Jong, J., Bast, A., & van der Vijgh, W. J. F. (1993) · PubMed · Cited by 23
Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts
Ramond, A., Sartorius, E., Mousseau, M., Ribuot, C., & Joyeux‐Faure, M. (2008) · Experimental Biology and Medicine · doi:10.3181/0706-rm-152 · Cited by 21
Fu, J., Yamamoto, K., Guan, Z., Kimura, S., & Iyanagi, T. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.04.030 · Cited by 20
Keller, A., Jackson, J. A., Peshock, R. M., et al. (1986) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910030603 · Cited by 19
Subacute Anthracycline Cardiotoxicity
Hengel, C. L., Russell, P. A., Gould, P. A., & Kaye, D. M. (2005) · Heart Lung and Circulation · doi:10.1016/j.hlc.2005.06.003 · Cited by 18
In vivo studies on adriamycin-induced lipid peroxidation and effects of ferrous ions.
Kappus, H., Muliawan, H., & Scheulen, M. E. (1980) · PubMed · Cited by 15
Cited by
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity
Tadokoro, T., Ikeda, M., Ide, T., Deguchi, H., Ikeda, S., Okabe, K., Ishikita, A., Matsushima, S., Koumura, T., Yamada, K.-I., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132747 · Cited by 655
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Metadata
- Authors
- Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L.
- Venue
- Journal of Molecular and Cellular Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 52
- Issue
- 6
- Pages
- 1213-1225
- ISSN
- 0022-2828 (ISSN-L)
- OpenAlex
- W2084304742
- Cited by
- 1,414
- References
- 134
- FWCI
- 37.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.